Evaluate the Safety of GABITRIL in Adults With Generalized Anxiety Disorder
A 12-Month, Open-Label, Flexible-Dosage Study to Evaluate the Safety of GABITRIL at Dosages up to 16mg/Day in Adults With Generalized Anxiety Disorder
1 other identifier
interventional
N/A
1 country
28
Brief Summary
To assess the long-term safety and tolerability of tiagabine treatment in patients with generalized anxiety disorder (GAD).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
28 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
August 1, 2003
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 1, 2005
CompletedFirst Submitted
Initial submission to the registry
September 27, 2005
CompletedFirst Posted
Study publicly available on registry
October 6, 2005
CompletedApril 12, 2023
April 1, 2023
1.5 years
September 27, 2005
April 11, 2023
Conditions
Interventions
Eligibility Criteria
Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.
Sponsors & Collaborators
- Cephalonlead
Study Sites (28)
Pivotal Research Center
Mesa, Arizona, 85210, United States
Southwestern Research
Beverly Hills, California, 90210, United States
Pharmacology Research Institut
Newport Beach, California, 92660, United States
Pharmacology Research Institut
Northridge, California, 91324, United States
Pacific Clinical Research Medi
Orange, California, 92868, United States
Radiant Research San Diego
San Diego, California, 92103, United States
Affiliated Research Institute
San Diego, California, 92108, United States
Radiant Research Denver
Denver, Colorado, 80212, United States
University of Connecticut
Farmington, Connecticut, 06030, United States
Clinical Neuroscience Solution
Jacksonville, Florida, 32216, United States
Clinical Neuroscience Solution
West Palm Beach, Florida, 33407, United States
Carman Research
Smyrna, Georgia, 30080, United States
Cunningham Clinical Research
Edwardsville, Illinois, 62025, United States
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
Summit Research Network Farmin
Farmington Hills, Michigan, 48336, United States
CNS Research Institute
Clementon, New Jersey, 08021, United States
Social Psychiatry Research Ins
Brooklyn, New York, 11235, United States
Fieve Clinical Services, Inc.
New York, New York, 10021, United States
Medical and Behavioral
New York, New York, 10023, United States
Medical Research Network
New York, New York, 10024, United States
Richard Weisler, MD and Assoc
Raleigh, North Carolina, 27609, United States
Summit Research Network Inc.
Portland, Oregon, 97210, United States
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
South East Health Consultants
Charleston, South Carolina, 29407, United States
Claghorn-Lesem Research
Bellaire, Texas, 77401, United States
Radiant Research Salt Lake
Salt Lake City, Utah, 84107, United States
Comprehensive Neuroscience Of
Falls Church, Virginia, 22041, United States
Summit Seattle Boren
Seattle, Washington, 98104, United States
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Charles Brown, MD
Cephalon
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- NON RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
September 27, 2005
First Posted
October 6, 2005
Study Start
August 1, 2003
Primary Completion
February 1, 2005
Last Updated
April 12, 2023
Record last verified: 2023-04